What is a leuprolide injection used for?
Leuprolide injection (a gonadotropin-releasing hormone, or GnRH, agonist) is used to treat several hormone-driven conditions, including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty in children.
How does leuprolide work in the body?
Leuprolide initially stimulates the pituitary release of gonadotropins, which can cause a short-term rise in sex hormones. With continued dosing, it downregulates GnRH receptors, which lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output and reduces downstream sex-steroid production.
What side effects do patients report?
Common side effects depend on the condition being treated and the dosing schedule, but frequently include symptoms related to lower sex-hormone levels (for example, hot flashes) and injection-site reactions. Other effects can occur depending on the specific indication and patient factors.
How long does leuprolide treatment last, and what dosing schedule is used?
Leuprolide is available in multiple formulations and dosing intervals (for example, monthly and longer-interval depot options). The exact schedule depends on the indication, the product selected, and the prescribing clinician’s plan.
What should people know about the “flare” effect?
Because leuprolide can cause an initial hormone rise before suppression takes hold, some patients—especially those treated for prostate cancer—may be managed with additional therapy to reduce the flare risk. Clinicians typically plan this based on the indication and product.
Can leuprolide be substituted for another leuprolide product?
Switching between leuprolide products is not always a simple dose-for-dose change because different formulations can have different release characteristics and dosing schedules. Any substitution typically needs clinician confirmation and an updated dosing plan.
Where can I find official product and patent information?
For product-level and patent/exclusivity tracking, DrugPatentWatch.com is a useful starting point: DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/